Literature DB >> 20306084

Combined correction of recovery effect and motion blur for SUV quantification of solitary pulmonary nodules in FDG PET/CT.

Ivayla Apostolova1, Rafael Wiemker, Timo Paulus, Sven Kabus, Thomas Dreilich, Jörg van den Hoff, Michail Plotkin, Janos Mester, Winfried Brenner, Ralph Buchert, Susanne Klutmann.   

Abstract

OBJECTIVE: We evaluate a fully data-driven method for the combined recovery and motion blur correction of small solitary pulmonary nodules (SPNs) in F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT).
METHODS: The SPN was segmented in the low-dose CT using a variable Hounsfield threshold and morphological constraints. The combined effect of limited spatial resolution and motion blur in the SPN's PET image was then modelled by an effective Gaussian point-spread function (psf). Both isotropic and non-isotropic psfs were used. To validate the method, PET/CT measurements of the NEMA/IEC spheres phantom were performed. The method was applied to 50 unselected SPNs <or=30 mm from routine patient care.
RESULTS: Recovery of standardised uptake value (SUV) in the phantom image was significantly improved by combined recovery and motion blur correction compared with recovery-only correction, particularly with the non-isotropic model (residual average error 10%). In the patient images, automated segmentation and fit of the effective psf worked properly in all cases. Volume-equivalent diameter ranged from 4.9 to 27.8 mm. Uncorrected maximum SUV ranged from 0.9 to 13.3. Compared with recovery-only correction, combined correction with the non-isotropic model resulted in a 'relevant' (>or=30%) SUV increase in 47 SPNs (94%).
CONCLUSIONS: Correction of both recovery and motion blur is mandatory for accurate SUV quantification of SPNs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306084     DOI: 10.1007/s00330-010-1747-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

1.  Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology.

Authors:  Thomas Beyer; Gerald Antoch; Todd Blodgett; Lutz F Freudenberg; Tim Akhurst; Stephan Mueller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-12       Impact factor: 9.236

2.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis.

Authors:  N Avril; S Bense; S I Ziegler; J Dose; W Weber; C Laubenbacher; W Römer; F Jänicke; M Schwaiger
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

3.  Design considerations for PET/CT tomographs.

Authors:  M Egger
Journal:  Nuklearmedizin       Date:  2005       Impact factor: 1.379

4.  Deep-inspiration breath-hold PET/CT of the thorax.

Authors:  Sadek A Nehmeh; Yusuf E Erdi; Gustavo S P Meirelles; Olivia Squire; Steven M Larson; John L Humm; Heiko Schöder
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

5.  Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system.

Authors:  Gerhard W Goerres; Ehab Kamel; Burkhardt Seifert; Cyrill Burger; Alfred Buck; Thomas F Hany; Gustav K Von Schulthess
Journal:  J Nucl Med       Date:  2002-11       Impact factor: 10.057

6.  Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET.

Authors:  Marc Hickeson; Mijin Yun; Alexander Matthies; Hongming Zhuang; Lars-Eric Adam; Lester Lacorte; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-02       Impact factor: 9.236

7.  Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images.

Authors:  Sang-June Park; Dan Ionascu; Joseph Killoran; Marcelo Mamede; Victor H Gerbaudo; Lee Chin; Ross Berbeco
Journal:  Phys Med Biol       Date:  2008-06-19       Impact factor: 3.609

8.  Respiratory motion correction in 3-D PET data with advanced optical flow algorithms.

Authors:  Mohammad Dawood; Florian Buther; Xiaoyi Jiang; Klaus P Schafers
Journal:  IEEE Trans Med Imaging       Date:  2008-08       Impact factor: 10.048

9.  Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors.

Authors:  Claude Nahmias; Lindi M Wahl
Journal:  J Nucl Med       Date:  2008-10-16       Impact factor: 10.057

10.  Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.

Authors:  Suk Chul Kim; Suk C Kim; Josef Machac; Borys R Krynyckyi; Karin Knesaurek; Daniel Krellenstein; Barbara Schultz; Allen Gribetz; Louis DePalo; Alvin Teirstein; Chun K Kim
Journal:  Ann Nucl Med       Date:  2008-05-23       Impact factor: 2.668

View more
  11 in total

1.  Variabilities of Magnetic Resonance Imaging-, Computed Tomography-, and Positron Emission Tomography-Computed Tomography-Based Tumor and Lymph Node Delineations for Lung Cancer Radiation Therapy Planning.

Authors:  Kishor Karki; Siddharth Saraiya; Geoffrey D Hugo; Nitai Mukhopadhyay; Nuzhat Jan; Jessica Schuster; Matthew Schutzer; Lester Fahrner; Robert Groves; Kathryn M Olsen; John C Ford; Elisabeth Weiss
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-05-06       Impact factor: 7.038

2.  Joint correction of respiratory motion artifact and partial volume effect in lung/thoracic PET/CT imaging.

Authors:  Guoping Chang; Tingting Chang; Tinsu Pan; John W Clark; Osama R Mawlawi
Journal:  Med Phys       Date:  2010-12       Impact factor: 4.071

3.  Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?

Authors:  Marius E Mayerhoefer; Helmut Prosch; Christian J Herold; Michael Weber; Georgios Karanikas
Journal:  Eur Radiol       Date:  2012-06-01       Impact factor: 5.315

Review 4.  Improved Detection of Small Pulmonary Nodules Through Simultaneous MR/PET Imaging.

Authors:  Fernando E Boada; Thomas Koesters; Kai Tobias Block; Hersh Chandarana
Journal:  Magn Reson Imaging Clin N Am       Date:  2017-02-22       Impact factor: 2.266

5.  Impact of the point spread function on maximum standardized uptake value measurements in patients with pulmonary cancer.

Authors:  S Gellee; J Page; B Sanghera; P Payoux; Thomas Wagner
Journal:  World J Nucl Med       Date:  2014-05

6.  Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.

Authors:  Christiaan Schiepers; Magnus Dahlbom
Journal:  Eur Radiol       Date:  2010-12-21       Impact factor: 5.315

7.  Background-based Delineation of Internal Tumor Volume in Static Positron Emission Tomography in a Phantom Study.

Authors:  Yangchun Chen; Xiangrong Chen; Ji-An Liu; Fanyong Li
Journal:  Asia Ocean J Nucl Med Biol       Date:  2016

8.  The applications of corrected standardized uptake values in the diagnosis of peripheral lung lesions.

Authors:  Ming Ming; Zhen G Wang; DaCheng Li; FengYu Wu; SiMin Liu; Bin Shi; Wei Xue
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

9.  Simulation Study of a Frame-Based Motion Correction Algorithm for Positron Emission Imaging.

Authors:  Héctor Espinós-Morató; David Cascales-Picó; Marina Vergara; Ángel Hernández-Martínez; José María Benlloch Baviera; María José Rodríguez-Álvarez
Journal:  Sensors (Basel)       Date:  2021-04-08       Impact factor: 3.576

10.  Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.

Authors:  Laure Fournier; Lioe-Fee de Geus-Oei; Daniele Regge; Daniela-Elena Oprea-Lager; Melvin D'Anastasi; Luc Bidaut; Tobias Bäuerle; Egesta Lopci; Giovanni Cappello; Frederic Lecouvet; Marius Mayerhoefer; Wolfgang G Kunz; Joost J C Verhoeff; Damiano Caruso; Marion Smits; Ralf-Thorsten Hoffmann; Sofia Gourtsoyianni; Regina Beets-Tan; Emanuele Neri; Nandita M deSouza; Christophe M Deroose; Caroline Caramella
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.